Craig C. Hopkinson, M.D., is a distinguished medical professional who currently holds the position of Executive Vice President, Research and Development, and Chief Medical Officer at Alkermes. Dr. Hopkinson's career is marked by a strong commitment to advancing medical science and improving patient outcomes. He joined Alkermes in 2014 and has since played a pivotal role in steering the company's research and development efforts. His leadership has been instrumental in the development and commercialization of several key products, including treatments for schizophrenia, bipolar I disorder, and alcohol dependence. Prior to his tenure at Alkermes, Dr. Hopkinson held significant positions in the pharmaceutical industry. He served as the Chief Medical Officer at Omthera Pharmaceuticals, where he was responsible for overseeing the clinical development of a novel omega-3 fatty acid therapy. Before that, he spent over a decade at Pfizer, where he held various roles in clinical research and development, contributing to the advancement of therapies across multiple therapeutic areas. Dr. Hopkinson's academic background is equally impressive; he earned his medical degree from the University of Cape Town, South Africa, and completed his residency and fellowship training at the University of Washington in Seattle. In his current role at Alkermes, Dr. Hopkinson is responsible for guiding the company's overall R&D strategy, which includes overseeing clinical development, medical affairs, and regulatory affairs. His strategic vision has been crucial in expanding Alkermes' pipeline and bringing innovative treatments to market. Under his leadership, the company has continued to focus on developing novel therapeutics for complex disorders, such as central nervous system diseases and addiction. Dr. Hopkinson's dedication to scientific excellence and patient care continues to drive Alkermes' mission to improve the lives of patients worldwide.